Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03704714
Other study ID # NU 17H08
Secondary ID STU00207793NU 17
Status Suspended
Phase Phase 1/Phase 2
First received
Last updated
Start date November 20, 2018
Est. completion date June 11, 2025

Study information

Verified date August 2022
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma. Monoclonal antibodies, such as nivolumab, interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy may work better in treating participants with diffuse large B-cell lymphoma.


Description:

PRIMARY OBJECTIVES: I. To identify the maximum tolerated dose (MTD) for the combination treatment of nivolumab and rituximab, cyclophosphamide, doxorubicin hydrochloride (doxorubicin), vincristine sulfate (vincristine), and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL). (Phase I) II. To assess the impact of nivolumab + R-CHOP on response by looking at complete response (CR) rates. (Phase II) SECONDARY OBJECTIVES: I. To look at preliminary efficacy as measured by overall response rate for combination nivolumab + R-CHOP. II. To assess the impact of nivolumab + R-CHOP on survival outcomes, specifically progression-free survival (PFS), overall survival (OS) and event-free-survival (EFS). III. To assess toxicity and tolerability of patients treated with nivolumab + R-CHOP. IV. To assess quality of life in patients treated with nivolumab + R-CHOP. EXPLORATORY OBJECTIVES: I. To explore the impact of the PD-1:PD-L1 regulatory axis and targeting this axis on the immune microenvironment. II. To identify the process of cachexia as a potential mechanism of resistance to anti-PD-1 therapy. OUTLINE: This is a phase I, dose-escalation study of nivolumab followed by a phase II study. Participants receive nivolumab intravenously (IV) over 30 minutes on day 1. Participants also receive rituximab IV on day 2, cyclophosphamide IV on day 2, doxorubicin hydrochloride IV over 3-5 hours on day 2, vincristine sulfate IV over 30 minutes on day 2, and prednisone orally (PO) on days 2-6 of course 1 and rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV over 3-5 hours on day 1, vincristine sulfate IV over 30 minutes on day 1, and prednisone PO on days 1-5 of courses 2-6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed for up to 18 months.


Recruitment information / eligibility

Status Suspended
Enrollment 30
Est. completion date June 11, 2025
Est. primary completion date December 11, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient must have a confirmed diagnosis of: - De novo DLBCL including the clinical subtypes of primary mediastinal, - cell/histiocyte-rich large B-cell lymphoma and intravascular DLBCL OR - De novo transformed DLBCL from follicular lymphoma (FL) OR - Any high grade CD20+ B-cell lymphoma per World Health Organization (WHO) 2016 OR - CD20+ aggressive B-cell lymphoma unclassifiable. - Patient must be deemed an appropriate candidate for R-CHOP therapy. - Patients must be naive to prior therapy for the study diagnosis. - Patient must have advanced stage III/IV early stage disease where provider determines single modality therapy with chemo-immunotherapy is most appropriate (i.e radiation deferred). - Patient must have measurable disease (defined as >= 1.5 cm in diameter) with correlated fludeoxyglucose F-18 (FDG)-avidity on positron emission tomography (PET) scan with Deauville score of 4 or 5 at time of diagnosis. - Patient must have Eastern Cooperative Oncology Group (ECOG) performance status =< 2. - Absolute neutrophil count (ANC) >= 1000/mm^3, independent of growth factor support or >= 500/mm^3 in cases of ongoing bone marrow involvement (in either case, these must be independent of transfusion support) documented =< 28 days prior to registration. - Platelets >= 100,000/mm^3, or >= 50,000 in cases of ongoing bone marrow involvement (In either case, these must be independent of transfusion support) documented =< 28 days prior to registration. - Total bilirubin =< 1.5 x upper limit of normal (ULN) documented =< 28 days prior to registration. - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) /alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SPGT]) =< 3 x ULN documented =< 28 days prior to registration. - Creatinine clearance >= 25 mL/min documented =< 28 days prior to registration. - Females of child-bearing potential (FOCBP) and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment period. - NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: - Has not undergone a hysterectomy or bilateral oophorectomy. - Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months). - Females of childbearing potential (FOCBP) must have a negative urine or serum pregnancy test within 7 days prior to registration on study. - Patients must have the ability to understand and willingness to sign a written informed consent prior to registration on study. Exclusion Criteria: - Patients who have received prior therapy intended to treat the study diagnosis are not eligible. - Patients who have received prior anti-PD-1/L1 therapy for any indication are not eligible. - Patients who require urgent cytoreductive therapy (e.g. surgery or radiation) are not eligible. - Subjects with known immunodeficiency, known autoimmune disease, or concurrent use of immunomodulatory agents are not eligible. - Patients who have a condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications =< 14 days prior to registration are not eligible. - NOTE: Inhaled steroids and adrenal replacement steroid doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted. - Patients with known central nervous system (CNS) involvement are not eligible. - Patients with an active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy are not eligible. - NOTE: Exceptions to this are as follows: localized non-melanotic skin cancer and any cancer that in the judgment of the investigator has been treated with curative intent and will not interfere with the study treatment plan and response assessment. Prostate and breast cancer patients undergoing hormone therapy with no currently active disease are eligible. - Patients with known human immunodeficiency virus (HIV) are not eligible. - Patients with clinically active hepatitis A, B, or C infections are not eligible. - NOTE: Patients with a history of hepatitis may be eligible if they have a normal titer. Such cases should be approved by the study principal investigator (PI). - Patients who have any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator?s opinion, could compromise the subject?s safety or put the study outcomes at risk are not eligible. - Pregnant or nursing females are not eligible. - Patients with uncontrolled intercurrent illness including, but not limited to, any of the following are not eligible: - Ongoing or active systemic infection. - Symptomatic congestive heart failure. - Myocardial infarction within 6 months prior to registration. - Unstable angina pectoris. - Uncontrolled or symptomatic cardiac arrhythmias. - Any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association Functional classification. - Psychiatric illness/social situations that would limit compliance with study requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide
Given IV
Doxorubicin Hydrochloride
Given IV
Biological:
Nivolumab
Given IV
Drug:
Prednisone
Given PO
Other:
Quality-of-Life Assessment
Ancillary studies
Biological:
Rituximab
Given IV
Drug:
Vincristine Sulfate
Given IV

Locations

Country Name City State
United States Northwestern University Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States Northwestern University- Lake Forest Hospital Lake Forest Illinois
United States Northwestern Medicine: Delnor, DuPage, Warrenville, Kishwaukee (West Region) Warrenville Illinois

Sponsors (3)

Lead Sponsor Collaborator
Northwestern University Bristol-Myers Squibb, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) for the combination treatment of nivolumab and R-CHOP To identify the MTD for the combination treatment of nivolumab and R-CHOP in patients with DLBCL, this will be established during Phase I using a modified 3+3 dose escalation. Up to 18 months
Primary Progression Free Survival (PFS) To assess the impact of nivolumab + R-CHOP on PFS at 18 months: This will be the proportion of patient that will be alive and progression free at 18 months. At 18 months
Secondary Overall response rate (ORR) Will be defined as the percentage of subjects with a confirmed complete response (CR) or partial response (PR) as assessed by the investigators using Lugano criteria. Up to 18 months
Secondary Overall survival (OS) rate OS rate at 18 months: OS will be measured from the date of enrollment to the date of death from any cause. At 18 months
Secondary Event-free survival (EFS) EFS rate at 18 months: EFS will be measured from the date of enrollment to the date of first documented disease progression, relapse, discontinuation of therapy for any reason, initiation of new anti-lymphoma therapy or death from any cause. At 18 months
Secondary Overall response rates as defined by the RECIL and LYRIC criteria RECIL and LYRIC criteria will be evaluated using scans at baseline. Up to 18 months
Secondary Frailty/Geriatric Assessments Frailty will be assessed using the Geriatric Assessment Tool as developed by the Cancer and Aging Group and the Fried Frailty Index. Up to 18 months
Secondary Incidence of Adverse Events Toxicity Assessment: Toxicity will be graded using the CTCAE v5.0 and the pro- CTCAE (patient reported symptoms). Up to 42 days after treatment discontinuation
Secondary Quality of life Assessment Quality of life with treatment will be measured using Patient Reported Outcomes Measurement Information System (PROMIS) based measures and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30). Up to 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Active, not recruiting NCT03671018 - A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00992446 - Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Phase 2
Completed NCT03263637 - Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Phase 1
Active, not recruiting NCT02633111 - DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Terminated NCT02151903 - Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL Phase 1/Phase 2
Completed NCT01919619 - Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Phase 2
Terminated NCT01874288 - A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL Phase 1/Phase 2
Completed NCT02847130 - Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Recruiting NCT05053971 - Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1/Phase 2
Completed NCT03677141 - A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02981914 - Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Early Phase 1
Completed NCT03483688 - A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects Phase 1
Terminated NCT05107856 - PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies Phase 1
Recruiting NCT06191887 - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Phase 1
Active, not recruiting NCT05201248 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma Phase 1
Terminated NCT03195010 - Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Phase 2
Recruiting NCT06052826 - Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study Phase 2
Completed NCT02424968 - CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Phase 2
Recruiting NCT04970901 - A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Phase 1